Scholarlink

<p>Nintedanib is widely used to slow disease progression and prevent acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung disease (PF-ILD). We retrospectively analysed patients who initiated nintedanib for IPF or PF-ILD between August 2019 and July 2023 across 15 institutions in Japan, focusing on prognosis and disease progression. Patients were divided into two groups based on whether they survived for ≥ 3 years after nintedanib initiation, and their characteristics were compared. We also evaluated factors associated with annual forced vital capacity (FVC) decline and acute exacerbations. A total of 413 patients (171 with IPF and 242 with PF-ILD) were included. Median survival was 1,177 days for IPF and 1,268 days for PF-ILD, with no significant difference (<i>P</i> = 0.20). Patients surviving &lt; 3 years were older (75.0 vs. 71.0 years), more frequently had resting arterial oxygen saturation (SpO<sub>2</sub>) &lt; 95% (44.5% vs. 18.0%), and lower body mass index (BMI) (21.9 vs. 24.1&#xa0;kg/m<sup>2</sup>). Additionally, patients with a BMI &lt; 22&#xa0;kg/m<sup>2</sup> showed greater annual relative FVC decline. In conclusion, patients with IPF and PF-ILD showed comparable outcomes following nintedanib treatment. Age ≥ 65 years, resting SpO<sub>2</sub> &lt; 95%, and BMI &lt; 22&#xa0;kg/m<sup>2</sup> were associated with shorter survival after nintedanib initiation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月27日

查看全文
  • Shiho Goda,
  • Tadaaki Yamada,
  • Yasuhiro Goto,
  • Sayaka Uda,
  • Akira Nakao,
  • Shinsuke Shiotsu,
  • Yuji Kukida,
  • Keiko Tanimura,
  • Akifumi Miyamoto,
  • Yuki Imasato,
  • Asuka Okada,
  • Isao Hasegawa,
  • Koji Date,
  • Yohei Matsui,
  • Shoki Morito,
  • Noeru Inoguchi,
  • Shuji Osugi,
  • Hayato Kawachi,
  • Naoya Nishioka,
  • Masahiro Iwasaku,
  • Shinsaku Tokuda,
  • Tomohiro Handa,
  • Koichi Takayama

摘要

Nintedanib is widely used to slow disease progression and prevent acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung disease (PF-ILD). We retrospectively analysed patients who initiated nintedanib for IPF or PF-ILD between August 2019 and July 2023 across 15 institutions in Japan, focusing on prognosis and disease progression. Patients were divided into two groups based on whether they survived for ≥ 3 years after nintedanib initiation, and their characteristics were compared. We also evaluated factors associated with annual forced vital capacity (FVC) decline and acute exacerbations. A total of 413 patients (171 with IPF and 242 with PF-ILD) were included. Median survival was 1,177 days for IPF and 1,268 days for PF-ILD, with no significant difference (P = 0.20). Patients surviving < 3 years were older (75.0 vs. 71.0 years), more frequently had resting arterial oxygen saturation (SpO2) < 95% (44.5% vs. 18.0%), and lower body mass index (BMI) (21.9 vs. 24.1 kg/m2). Additionally, patients with a BMI < 22 kg/m2 showed greater annual relative FVC decline. In conclusion, patients with IPF and PF-ILD showed comparable outcomes following nintedanib treatment. Age ≥ 65 years, resting SpO2 < 95%, and BMI < 22 kg/m2 were associated with shorter survival after nintedanib initiation.